SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 10-K: (Original Filing)
[FORM 10-K For the fiscal year ended December 31, 2009 OR For the transition period from ________________ to ________________ 001-15643 SKYSTAR BIO-PHARMACEUTICAL COMPANY Nevada 33-0901534 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China N/A (Zip Code) (8629) 8819-3188 Title of] [SERVICES AGREEMENT This SERVICES AGREEMENT (this “Agreement”), dated as of March 30, 2010, by and between Skystar Bio-Pharmaceutical Company, a Nevada corporation (the “Company”), and R. Scott Cramer, an individual, whose address is 1012 Lewis Drive Winter Park, Florida 32789-2225 (“Consultant”). The Company and the Consultant are collectively referred to herein as the “Parties.” RECITALS: A. B. NOW, THEREFORE, in] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Weibing Lu, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bennet P. Tchaikovsky, certify that: 1. I have reviewed this annual report on Form 10-K of Skystar Bio-Pharmaceutical Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Weibing Lu Chief Executive Officer March 31, 2010 EX-32.1 9 v179475_ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer March 31, 2010 EX-32.2 10 v179475_ex32-2.htm] [Contract Registration No. 20096101021102 Technical Cooperation Agreement Name of Project: Cooperative Research of Party A: Xian Tianxing Bio-Pharmaceutical Co., Ltd. (stamp) Party B: Fourth Military Medical University (stamp) China Place of Execution: Xi’an, Shaanxi Province, China Date of Effective: September 23, 2009 Term of Validity: From September 23, 2009 to the date when the performances under the terms of the]